Clinical TrialsPYX-201 showed an efficacy signal in head and neck squamous cell carcinoma (HNSCC) patients that stood out from other tumor types.
Financial OutlookPyxis had approximately $146M in cash and cash equivalents, which is believed to be sufficient to support operations into the second half of 2026.
Market PotentialAnalysts see a base-case potential of approximately 50% upside, with a risk-reward profile that is attractive based on conservative investor sentiment.